FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061844429> ?p ?o ?g. }

• W2061844429 endingPage "3" @default.
• W2061844429 startingPage "1" @default.
• W2061844429 abstract "INTRODUCTION The London Olympics have just finished. Official reports will soon become available on how many athletes participating in the games had asthma. However, as in the past [1], prevalence data will often be deducted by the number of athletes using inhaled beta-2 agonists that, according to the new 2012 World Anti-Doping Agency (WADA) rules [2▪], were on this occasion permitted for all the most commonly used short-acting and long-acting drugs, just following a declaration of use made by the athletes themselves. This self-reporting will largely influence the accuracy of estimates, which will not distinguish between clinical asthma and exercise-induced bronchoconstriction (EIB) without clinical asthma, as recently requested [3▪]. Moreover, no information will be provided on how the diagnosis of asthma was made, on the presence of comorbid conditions such as sensitization or allergic rhinitis, as well as on whether the management of asthmatic athletes followed the international asthma guidelines, with special reference to the concomitant use of long-acting beta agonists and inhaled corticosteroids (at present, permitted by the WADA rules). In two recent articles, the British Medical Journal called attention to the relevance of an optimal management of asthma in sport medicine, as well as to the need of ‘making the most of the Olympics’ by taking advantage of the educational impact that the ‘shop window’ of elite athletes may have on the general public [4,5]. Allergic Rhinitis and its Impact on Asthma (ARIA) is an international initiative that was launched after a World Health Organization meeting held in 1999. Its aim is to provide and diffuse validated guidelines for the management of allergic rhinitis and the concomitant frequent involvement of the lower airways. The original document, published in 2001 [6], translated into 42 languages and diffused in 64 countries, was first updated in 2008 [7] and then in 2010 [8▪▪] on the basis of an improved methodology (GRADE) to guarantee evidence-based statements and support the strength of recommendations given [9]. In 2006, an ARIA document was developed to specifically address the needs of elite athletes suffering from allergic rhinitis [10]. The achievements obtained in the 10 years since the publication of the first ARIA document [11] make the above studies an internationally recognized guidance for the management of rhinitis in the general population and in athletes, as evidenced by the 1633 citations currently in the scientific literature [12]. This document aims at providing three simple statements and some practical suggestions based on the evidence and recommendations of the ARIA guidelines, which might be useful in preventing asthma and EIB not only in athletes but also in the 25% of the general population with allergic rhinitis who occasionally exercise. STATEMENT 1: RHINITIS HAS A HIGH AND INCREASING PREVALENCE IN ATHLETES In a review of 16 cross-sectional studies performed in 10 328 athletes, rhinitis has been reported to occur with prevalence rates of up to 41%, and with an increasing incidence over the years [13▪]. The prevalence of rhinitis is higher in cold air sport disciplines: 48.6% in skiers [14]. However, high prevalence rates are also reported at Summer Olympics: 29.0% in the Australian Delegation at Sydney 2000 [15], and 25.3 and 27.0% in the Italian pre-Olympic athletes at Sydney 2000 and Beijing 2008, respectively [16]. Furthermore, the transient immunodeficiency associated with intense training has been shown to favor the occurrence of upper respiratory tract infections and infectious rhinitis in close temporal proximity of competitions [17]. Accordingly, it was expected that at least one out of four athletes participating in the London Olympics would be suffering from rhinitis. STATEMENT 2: DIAGNOSING RHINITIS IN ATHLETES IS VERY IMPORTANT Rhinitis is often considered a trivial disease and is largely underdiagnosed and self-managed in athletes. However, rhinitis has been shown to significantly affect the quality-of-life and performance of athletes, also in relation to the effects of drugs taken to control clinical symptoms [18]. Moreover, rhinitis represents a well known risk factor for asthma [6,10] and for EIB, a condition often occurring in athletes, even in the absence of clinical underlying asthma [3▪]. Certainly, rhinitis exerts an additive negative effect on the well being and disease control of athletes with asthma [19]. Therefore, the ARIA recommendation assessment of patients with rhinitis for co-existent asthma should also be extended to athletes with rhinitis. As clinical symptoms are poorly predictive of asthma/EIB and baseline pulmonary function tests are often normal [20], an accurate clinical examination should be carried out by a trained physician on athletes suffering from rhinitis. This examination should be complemented by a specific allergy questionnaire – such as the Allergy Questionnaire for Athletes, AQUA [21] – and eventually by provocation tests [22▪]. STATEMENT 3: RHINITIS SHOULD BE TREATED IN ATHLETES ACCORDING TO EVIDENCE-BASED GUIDELINES WITH SPECIAL CONSIDERATIONS FOR MODIFYING FACTORS In addition to implementing the general ARIA recommendations for the treatment of allergic rhinitis [6,7,8▪▪,9], special considerations for factors that modify these recommendations should be taken into account for athletes. These relate to the potential side-effects of some drugs, as well as to the limitations set by WADA in the 2012 list of prohibited substances [2▪]. ARIA guidelines state that individuals with allergic rhinitis and the frequently occurring concomitant involvement of the lower airways should receive a combined treatment for the nose and the lung and lay-friendly information on the optimal management of their symptoms [6,7,8▪▪]. This is particularly important for athletes with EIB in whom the bypass of the nose (which filters, warms and moisturizes air) increases the negative effects of the hyperventilation through the mouth, leading to bronchial epithelial damage and clinical symptoms [3▪,23]. Inhaled and nasal steroids, permitted by WADA, represent the treatment of choice [6,7,8▪▪], because they are very effective in controlling inflammation and symptoms of both upper and lower airways while reducing the need for rescue medications (vasoconstrictors and bronchodilators) undergoing clinical and antidoping limitations for potential side-effects and induction of tolerance. Ephedrine, methylephedrine and pseudoephedrine are in fact prohibited by WADA when their concentration in urine exceeds the allowed threshold. Although there are no restrictions for the use of antihistamines, it is well known that – particularly first-generation molecules – may have potential side-effects on the cardiovascular and nervous system and are known to induce sedation and fatigue in many patients. Therefore, the use of second-generation molecules must be preferred, and the potential side-effects should be carefully monitored in athletes, in relation to the relevant cardiovascular loads and the need for unaffected reaction times for optimal performances. Preventive measures should also be undertaken to limit exposure to environmental factors (air humidity and temperature, content in pollutants and allergens responsible for sensitization in allergic athletes) that may trigger symptoms and affect performances during training and competition. Hopefully, these simple concepts will help athletes suffering from rhinitis in sharing the motto ‘Yes, (with allergy) we can’ [24]. Moreover, athletes may become ambassadors to broadcast this positive message to the hundreds of millions of other allergy sufferers around the globe. Acknowledgements None. Conflicts of interest The ARIA members reviewed and commented the text drafted according to the outline agreed upon during an ARIA meeting, and approved the final document. None disclosed." @default.
• W2061844429 created "2016-06-24" @default.
• W2061844429 creator A5000373583 @default.
• W2061844429 creator A5001308400 @default.
• W2061844429 creator A5004123017 @default.
• W2061844429 creator A5004330554 @default.
• W2061844429 creator A5004878337 @default.
• W2061844429 creator A5006129133 @default.
• W2061844429 creator A5009413838 @default.
• W2061844429 creator A5015311592 @default.
• W2061844429 creator A5022142463 @default.
• W2061844429 creator A5024384991 @default.
• W2061844429 creator A5030629710 @default.
• W2061844429 creator A5032010171 @default.
• W2061844429 creator A5032018810 @default.
• W2061844429 creator A5037092064 @default.
• W2061844429 creator A5038822245 @default.
• W2061844429 creator A5039510014 @default.
• W2061844429 creator A5040903631 @default.
• W2061844429 creator A5041944228 @default.
• W2061844429 creator A5046715953 @default.
• W2061844429 creator A5050755384 @default.
• W2061844429 creator A5051663612 @default.
• W2061844429 creator A5052175038 @default.
• W2061844429 creator A5055660760 @default.
• W2061844429 creator A5055677585 @default.
• W2061844429 creator A5056266797 @default.
• W2061844429 creator A5063051968 @default.
• W2061844429 creator A5071868716 @default.
• W2061844429 creator A5073511686 @default.
• W2061844429 creator A5075387555 @default.
• W2061844429 creator A5076454807 @default.
• W2061844429 creator A5077174735 @default.
• W2061844429 creator A5079643670 @default.
• W2061844429 creator A5082009698 @default.
• W2061844429 creator A5083348221 @default.
• W2061844429 creator A5084613159 @default.
• W2061844429 date "2013-02-01" @default.
• W2061844429 modified "2023-10-18" @default.
• W2061844429 title "What we should learn from the London Olympics" @default.
• W2061844429 cites W1491412557 @default.
• W2061844429 cites W1600513579 @default.
• W2061844429 cites W1966370024 @default.
• W2061844429 cites W1972540554 @default.
• W2061844429 cites W1974508853 @default.
• W2061844429 cites W1997580502 @default.
• W2061844429 cites W2007863621 @default.
• W2061844429 cites W2014457158 @default.
• W2061844429 cites W2032982186 @default.
• W2061844429 cites W2046036256 @default.
• W2061844429 cites W2096210343 @default.
• W2061844429 cites W2107437761 @default.
• W2061844429 cites W2122765413 @default.
• W2061844429 cites W2122854757 @default.
• W2061844429 cites W2136712715 @default.
• W2061844429 cites W2150976630 @default.
• W2061844429 cites W2164132449 @default.
• W2061844429 cites W2331156797 @default.
• W2061844429 cites W2466487973 @default.
• W2061844429 doi "https://doi.org/10.1097/aci.0b013e32835c1b73" @default.
• W2061844429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23222179" @default.
• W2061844429 hasPublicationYear "2013" @default.
• W2061844429 type Work @default.
• W2061844429 sameAs 2061844429 @default.
• W2061844429 citedByCount "9" @default.
• W2061844429 countsByYear W20618444292014 @default.
• W2061844429 countsByYear W20618444292015 @default.
• W2061844429 countsByYear W20618444292016 @default.
• W2061844429 countsByYear W20618444292017 @default.
• W2061844429 countsByYear W20618444292018 @default.
• W2061844429 countsByYear W20618444292019 @default.
• W2061844429 countsByYear W20618444292021 @default.
• W2061844429 crossrefType "journal-article" @default.
• W2061844429 hasAuthorship W2061844429A5000373583 @default.
• W2061844429 hasAuthorship W2061844429A5001308400 @default.
• W2061844429 hasAuthorship W2061844429A5004123017 @default.
• W2061844429 hasAuthorship W2061844429A5004330554 @default.
• W2061844429 hasAuthorship W2061844429A5004878337 @default.
• W2061844429 hasAuthorship W2061844429A5006129133 @default.
• W2061844429 hasAuthorship W2061844429A5009413838 @default.
• W2061844429 hasAuthorship W2061844429A5015311592 @default.
• W2061844429 hasAuthorship W2061844429A5022142463 @default.
• W2061844429 hasAuthorship W2061844429A5024384991 @default.
• W2061844429 hasAuthorship W2061844429A5030629710 @default.
• W2061844429 hasAuthorship W2061844429A5032010171 @default.
• W2061844429 hasAuthorship W2061844429A5032018810 @default.
• W2061844429 hasAuthorship W2061844429A5037092064 @default.
• W2061844429 hasAuthorship W2061844429A5038822245 @default.
• W2061844429 hasAuthorship W2061844429A5039510014 @default.
• W2061844429 hasAuthorship W2061844429A5040903631 @default.
• W2061844429 hasAuthorship W2061844429A5041944228 @default.
• W2061844429 hasAuthorship W2061844429A5046715953 @default.
• W2061844429 hasAuthorship W2061844429A5050755384 @default.
• W2061844429 hasAuthorship W2061844429A5051663612 @default.
• W2061844429 hasAuthorship W2061844429A5052175038 @default.
• W2061844429 hasAuthorship W2061844429A5055660760 @default.
• W2061844429 hasAuthorship W2061844429A5055677585 @default.
• W2061844429 hasAuthorship W2061844429A5056266797 @default.

• next